logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Tag: Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers ( AβOs ), has been granted...

Read More

October 25, 2022

0

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating...

Read More

October 28, 2022

0

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers ( AβOs ), has been granted...

Read More

October 25, 2022

0

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating...

Read More

October 28, 2022

0

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody, which selectively targets toxic soluble amyloid beta oligomers ( AβOs ), has been granted...

Read More

October 25, 2022

0

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage with novel products that had some earlier, encouraging test results, whose technologies and lead products must have demonstrated  improvement over current treatments of devastating...

Read More

October 28, 2022

0

  • 1

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy